Could not open /dev/vmmon
forum.manjaro.org/t/could-not-open-dev-vmmon/21431
May 14, 2024
3
ESMO Virtual Congress 2020: The Final Overall Survival (OS) Analysis From the PROfound Study and IPATential150, Ipatasertib Plus Abiraterone (abi) vs Placebo Plus Abi in Metastatic Castration-Resistant Prostate Cancer (mCRPC) - Invited Discussion
www.urotoday.com/conference-highlights/esmo-2020/prostate-cancer/124589-esmo-virtual-congress-2020-invited-discussant-lba4-ipatential150-and-610o-profound.html
May 14, 2024
12
Choosing First-Line Systemic Therapy for Newly Diagnosed Metastatic Hormone Sensitive Prostate Cancer
www.urotoday.com/journal/everyday-urology-oncology-insights/articles/117829-choosing-first-line-systemic-therapy-for-newly-diagnosed-mhspc.html
May 14, 2024
9
APCCC 2021: DNA Repair Defect Aberrations – What Are the Differences Between Them and What Is the Impact on Patient Management?
www.urotoday.com/conference-highlights/apccc-2021/133282-apccc-2021-dna-repair-defect-aberrations-what-are-the-differences-between-them-and-what-is-the-impact-on-patient-management.html
May 14, 2024
10
ASCO GU 2022: PROpel: Phase III Trial of Olaparib and Abiraterone Versus Placebo and Abiraterone as First-Line Therapy for Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC)
www.urotoday.com/conference-highlights/asco-gu-2022/asco-gu-2022-prostate-cancer/135383-asco-gu-2022-propel-phase-iii-trial-of-olaparib-and-abiraterone-versus-placebo-and-abiraterone-as-first-line-therapy-for-patients-with-metastatic-castration-resistant-prostate-cancer-mcrpc.html
May 14, 2024
13
ASCO GU 2022: ARASENS Trial Overall Survival With Darolutamide Versus Placebo in Combination With ADT and Docetaxel for mHSPC
www.urotoday.com/conference-highlights/asco-gu-2022/asco-gu-2022-prostate-cancer/135403-asco-gu-2022-overall-survival-with-darolutamide-versus-placebo-in-combination-with-androgen-deprivation-therapy-and-docetaxel-for-metastatic-hormone-sensitive-prostate-cancer-in-the-phase-3-arasens-trial.html
May 14, 2024
3
ASCO GU 2024: Phase 1b/2 Study of Pembrolizumab Plus Belzutifan and Belzutifan Alone in Patients with Docetaxel-treated mCRPC: KEYNOTE-365 Cohort J
omnivore.app/amyken/asco-gu-2024-phase-1-b-2-study-of-pembrolizumab-plus-belzutifan--18d4db75b40
Jan 28, 2024
omnivore.app-ESMO 2023 Invited Discussant More Than Therapy Alone.pdf
typeset.io/library/esmo2023-3pj4gedk/omnivore-app-esmo-2023-invited-discussant-more-than-therapy-n98omj8v
Nov 19, 2023
1
(3) 【张捷聊教育】美国重提学徒制与AI时代的知识私有 - YouTube
www.youtube.com/watch?v=udhQClPZ3Ok
Nov 14, 2023
1
(3) Cubox AI Reading Assistant - YouTube
www.youtube.com/watch?v=CAfwJcvvjnE
Nov 14, 2023
1
(3) Taking notes from YouTube videos in Obsidian - YouTube
www.youtube.com/watch?v=qjWq4ck2-0o
Nov 13, 2023
1
(3) Continence preserving Robotic Radical Prostatectomy (Hood Technique) - With audio | Surgical Videos - YouTube
www.youtube.com/watch?v=3-KDN6yfkU4
Nov 13, 2023
1
(2) Hood Technique - Robotic Radical Prostatectomy by Dr Ash Tewari - YouTube
www.youtube.com/watch?v=cO1PjfJydHo
Nov 13, 2023
1
你真的能区分临床中观察性研究与试验性研究吗？ - 爱科学
www.iikx.com/news/statistics/1578.html
Nov 10, 2023
1
图说临床研究如何分类
www.ttdoc.cn/article/266.jhtml
Nov 10, 2023
8
ESMO 2023: ARASTEP: Darolutamide + ADT in Patients with High-Risk BCR Prostate Cancer – A Phase 3 Study
www.urotoday.com/conference-highlights/esmo-2023/esmo-2023-prostate-cancer/147468-esmo-2023-tip-arastep-darolutamide-adt-in-patients-with-high-risk-bcr-of-prostate-cancer-a-phase-3-randomized-double-blind-placebo-controlled-study.html
Nov 4, 2023
1
ESMO 2023: ARASTEP: Darolutamide + ADT in Patients with High-Risk BCR Prostate Cancer – A Phase 3 Study
omnivore.app/amyken/esmo-2023-arastep-darolutamide-adt-in-patients-with-high-risk-bc-18b7ab9f269
Nov 4, 2023
1
Chronic Glucocorticoid Use and Risk for Advanced Prostate Cancer at Presentation: A SEER-Medicare Cohort Study.
omnivore.app/amyken/chronic-glucocorticoid-use-and-risk-for-advanced-prostate-cancer-18b22b1bc90
Oct 13, 2023
Discovery of BWA-522, a First-in-Class and Orally Bioavailable PROTAC Degrader of the Androgen Receptor Targeting N-Terminal Domain for the Treatment of Prostate Cancer.
omnivore.app/amyken/discovery-of-bwa-522-a-first-in-class-and-orally-bioavailable-pr-18a95808fb1
Sep 19, 2023
1
2020_Suzuki et al_Comparison of the Perioperative and Postoperative Outcomes of Ileal Conduit and.pdf
typeset.io/library/shu-niao-guan-zao-kou-1vw1ka7g/2020-suzuki-et-al-comparison-of-the-perioperative-and-2d86cjsf
Jul 9, 2023
Avelumab First-Line Maintenance for Advanced Urothelial Carcinoma
www.practiceupdate.com/c/151207/67/25/?elsca1=emc_enews_weekinreview&elsca2=email&elsca3=practiceupdate_blc&elsca4=blc&elsca5=newsletter&rid=OTczNzE3ODE2ODYS1&lid=37818878
May 5, 2023
2
7 Ways to Retain More of Every Book You Read
jamesclear.com/reading-comprehension-strategies
Apr 22, 2023
4
2023版CSCOPC指南更新——循证指引mHSPC治疗新时代_研究_负荷_患者
www.sohu.com/a/648453046_121119268
Apr 20, 2023
1
EAU 2023: Is There a Role for Local Therapy to the Bladder in Patients with Oligometastatic Disease?
www.urotoday.com/conference-highlights/eau-annual-congress-2023/eau-2023-bladder-cancer/143146-eau-2023-is-there-a-role-for-local-therapy-to-the-bladder-in-patients-with-oligometastatic-disease.html
Mar 26, 2023
11
Glasp Vs Readwise. Which Knowledge Management Tool is Better?
www.hongkiat.com/blog/glasp-vs-readwise/
Mar 26, 2023
1
ASCO 2019: Alliance A031201: A Phase III Trial of Enzalutamide Versus Enzalutamide, Abiraterone, and Prednisone for Metastatic Castration Resistant Prostate Cancer - Medical Oncologist Perspective
www.urotoday.com/conference-highlights/asco-2019-annual-meeting/asco-2019-prostate-cancer/112895-asco-2019-alliance-a031201-a-phase-iii-trial-of-enzalutamide-versus-enzalutamide-abiraterone-and-prednisone-for-metastatic-castration-resistant-prostate-cancer.html
Oct 31, 2022
2
[Neuroendocrine prostate cancer: Natural history, molecular features, therapeutic management and future directions]
www.urotoday.com/recent-abstracts/urologic-oncology/prostate-cancer/97191-neuroendocrine-prostate-cancer-natural-history-molecular-features-therapeutic-management-and-future-directions.html
Oct 12, 2022
1
ASCO 2022: Radiographic Progression in the Absence of PSA Progression in Patients with mHSPC: Post Hoc Analysis of ARCHES
www.urotoday.com/conference-highlights/asco-2022/asco-2022-prostate-cancer/137711-asco-2022-radiographic-progression-in-the-absence-of-psa-progression-in-patients-with-mhspc-post-hoc-analysis-of-arches.html
Jul 8, 2022
1
Cubox 个人碎片知识库
cubox.pro/my/card?id=ff80808181ae5ebd0181c9574a217e94
Jul 4, 2022
Predictive Value of Isolated High-Grade Prostatic Intraepithelial Neoplasia in Detecting Clinically Significant Prostate Cancer Risk
www.practiceupdate.com/c/136097/1/3/?elsca1=emc_enews_expert-insight&elsca2=email&elsca3=practiceupdate_uro&elsca4=urology&elsca5=newsletter&rid=OTczNzE3ODE2ODYS1&lid=20845153
Jul 4, 2022
6
EAU 2020: Primary Treatment of Pelvic Lymph Node Metastatic Prostate Cancer - Surgery Only
www.urotoday.com/conference-highlights/eau-2020/prostate-cancer/123223-eau-2020-primary-treatment-of-pelvic-lymph-node-metastatic-prostate-cancer-surgery-only.html
Jun 4, 2022
2
The PARP Partnering Predicament
www.urotoday.com/center-of-excellence/mcrpc-treatment/from-the-editor/129632-the-parp-partnering-predicament.html
May 21, 2022
9
Progressive Summarization: A Practical Technique for Designing Discoverable Notes
fortelabs.co/blog/progressive-summarization-a-practical-technique-for-designing-discoverable-notes/
May 21, 2022
2
ASCO GU 2022: The TRAP Trial: Targeting Resistant Prostate Cancer, with or without DNA Repair Defects, Using the Combination of Ceralasertib and Olaparib
www.urotoday.com/conference-highlights/asco-gu-2022/asco-gu-2022-prostate-cancer/135739-asco-gu-2022-the-trap-trial-targeting-resistant-prostate-cancer-with-or-without-dna-repair-defects-using-the-combination-of-ceralasertib-and-olaparib.html
Mar 26, 2022
2
ASCO GU 2022: Treatment Outcomes for mCRPC Following Progression on Upfront ADT with Androgen Receptor Pathway Inhibitors for mCSPC
www.urotoday.com/conference-highlights/asco-gu-2022/asco-gu-2022-prostate-cancer/135740-asco-gu-2022-treatment-outcomes-for-mcrpc-following-progression-on-upfront-adt-with-androgen-receptor-pathway-inhibitors-for-mcspc.html
Mar 12, 2022
2
ARAMIS: Favorable Overall Survival and Safety Findings for Darolutamide in Nonmetastatic Castration-Resistant Prostate Cancer
www.urotoday.com/journal/everyday-urology-oncology-insights/articles/123290-aramis-favorable-overall-survival-and-safety-findings-for-darolutamide-in-non-metastatic-castration-resistant-prostate-cancer.html
Feb 20, 2022
5
ASCO 2020: Darolutamide Demonstrates Significant Improvement in Overall Survival in nmCRPC -The ARAMIS Trial
www.urotoday.com/conference-highlights/asco-2020/asco-2020-prostate-cancer/121805-asco-2020-darolutamide-demostrates-signifincat-improvement-in-overall-survival-in-nmcrpc-the-aramis-trial.html
Feb 20, 2022
1
ASCO GU 2022: Discussion - PROpel and MAGNITUDE
www.urotoday.com/conference-highlights/asco-gu-2022/asco-gu-2022-prostate-cancer/135414-asco-gu-2022-propel-and-magnitude-discussion.html
Feb 19, 2022
6
ASCO GU 2022: First Results of the MAGNITUDE: Phase 3 Study of Niraparib With Abiraterone Acetate and Prednisone As First-Line Therapy in Patients With mCRPC With and Without HRR Gene Alterations
www.urotoday.com/conference-highlights/asco-gu-2022/asco-gu-2022-prostate-cancer/135402-asco-gu-2022-first-results-of-the-magnitude-phase-3-study-of-niraparib-with-abiraterone-acetate-and-prednisone-as-first-line-therapy-in-patients-with-mcrpc-with-and-without-hrr-gene-alterations.html
Feb 19, 2022
10
Determining the diagnostic value of PSMA-PET/CT imaging in patients with persistent high prostate specific antigen levels and negative prostate biopsies
www.sciencedirect.com/science/article/pii/S1078143921003112
Feb 8, 2022
11
ASCO GU 2021: Concordance of BRCA1 and BRCA2, and ATM Mutations Identified in Matched Tumor Tissue and ctDNA in Men mCRPC Screened in the PROfound Study
www.urotoday.com/conference-highlights/asco-gu-2021/prostate-cancer/128072-asco-gu-2021-concordance-of-brca1-brca2-brca-and-atm-mutations-identified-in-matched-tumor-tissue-and-ctdna-in-men-mcrpc-screened-in-the-profound-study.html
Jul 2, 2021
1
PARP Inhibitors in Prostate Cancer
www.urotoday.com/library-resources/advanced-prostate-cancer/122683-parp-inhibitors-in-prostate-cancer.html
Jun 11, 2021
3
CDK12-Altered Prostate Cancer: Clinical Features and Therapeutic Outcomes to Standard Systemic Therapies, Poly (ADP-Ribose) Polymerase Inhibitors, and PD-1 Inhibitors | JCO Precision Oncology
ascopubs.org/doi/full/10.1200/PO.19.00399
May 12, 2021
1
CDK12-Altered Prostate Cancer: Clinical Features and Therapeutic Outcomes to Standard Systemic Therapies, Poly (ADP-Ribose) Polymerase Inhibitors, and PD-1 Inhibitors | JCO Precision Oncology
ascopubs.org/doi/full/10.1200/PO.19.00399?utm_source=TrendMD&utm_medium=cpc&utm_campaign=JCO_PO_TrendMD_0
May 12, 2021
1
Metastatic Hormone-Sensitive Prostate Cancer (mHSPC): Advances and Treatment Strategies in the First-Line Setting
link.springer.com/article/10.1007/s40487-020-00119-z
Mar 6, 2021
1
ASCO GU 2021: Discussion: Molecular Correlates of Response to Apalutamide in nmCRPC and Final Results from ACIS, Androgen Annihilation with Abiraterone and Apalutamide in Chemo-Naïve mCRPC
www.urotoday.com/conference-highlights/asco-gu-2021/prostate-cancer/127872-asco-gu-2021-discussion-molecular-correlates-of-response-to-apalutamide-in-nmcrpc-and-final-results-from-acis-androgen-annihilation-with-abiraterone-and-apalutamide-in-chemo-naive-mcrpc.html
Feb 18, 2021
8
ASCO GU 2021: Survival Outcomes in Patients with Metastatic Castration-Sensitive Prostate Cancer (mCSPC): A Real-World Evidence Study
www.urotoday.com/conference-highlights/asco-gu-2021/prostate-cancer/127844-asco-gu-2021-survival-outcomes-in-patients-with-metastatic-castration-sensitive-prostate-cancer-mcspc-a-real-world-evidence-study.html
Feb 18, 2021
2